MN33-63 是一种具有广谱抗癌活性的 Bcl-2 抑制剂、caspase-3 激活剂和 DNA 交联剂,可提高 SN-38 (MS-K87916) 的水溶性,呈剂量依赖性抑制肿瘤生长和增殖且无明显毒性,通过解除线粒体凋亡通路的抑制状态启动凋亡 (apoptosis) 程序、抑制 Topo I 活性并经泛素-蛋白酶体和自噬-溶酶体通路促进其降解,同时诱导 DNA 交联、G2/M 期细胞周期阻滞和癌细胞迁移抑制,并通过线粒体通路诱导癌细胞凋亡,可用于结直肠癌、宫颈癌、肝细胞癌、肺腺癌、胃癌的研究。
MN33-63
产品编号: MS-M26930 分子式: C27H26Cl2N3Na2O9P 分子量: 684.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MN33-63 是一种具有广谱抗癌活性的 Bcl-2 抑制剂、caspase-3 激活剂和 DNA 交联剂,可提高 SN-38 (MS-K87916) 的水溶性,呈剂量依赖性抑制肿瘤生长和增殖且无明显毒性,通过解除线粒体凋亡通路的抑制状态启动凋亡 (apoptosis) 程序、抑制 Topo I 活性并经泛素-蛋白酶体和自噬-溶酶体通路促进其降解,同时诱导 DNA 交联、G2/M 期细胞周期阻滞和癌细胞迁移抑制,并通过线粒体通路诱导癌细胞凋亡,可用于结直肠癌、宫颈癌、肝细胞癌、肺腺癌、胃癌的研究。

生物实验数据

生物活性 MN33-63 is a Bcl-2 inhibitor, caspase-3 activator, and DNA crosslinker with broad-spectrum anticancer activity that enhances the water solubility of SN-38 (MS-K87916) and inhibits tumor growth and proliferation in a dose-dependent manner without obvious toxicity; it relieves the suppressed state of the mitochondrial apoptotic pathway to initiate the apoptosis program, inhibits Topo I activity, and promotes its degradation via the ubiquitin-proteasome and autophagy-lysosome pathways, while inducing DNA crosslinking, G2/M cell cycle arrest, and inhibition of cancer cell migration, and inducing cancer cell apoptosis through the mitochondrial pathway, and can be used for research on colorectal cancer, cervical cancer, hepatocellular carcinoma, lung adenocarcinoma, and gastric cancer.
IC50 & Target

Caspase 3

 

Bcl-2

 

Topoisomerase I

 

体外研究
(In Vitro)

MN33-63 可强效抑制 HCT-15、HeLa、HepG2、A549、HGC-27 和 CT26 癌细胞的增殖,72 h 时的 IC50 为 0.05 nM-306.10 nM,其中对 HGC-27 细胞的活性最强。
MN33-63 (100 nM; 24-48 h) 可强效抑制 CT26 细胞迁移,使 24 h 时的迁移率为 2.51%,48 h 时的迁移率为 4.42%。
MN33-63 (100 nM; 48 h) 可在 CT26 细胞中诱导强烈的 G2/M 期阻滞,孵育 48 h 后有 59.8% 的细胞处于 G2/M 期。
MN33-63 (100 nM; 48 h) 可诱导 61.10%的 CT26 细胞发生凋亡,孵育 48 h 后,其促凋亡活性强于 chlormethine hydrochloride (MS-M01996) (CH)、SN-38 (MS-K87916) 或二者的物理混合物。
MN33-63 (1-10000 nM, 1 μM; 72 h) 可在 72 h 内以剂量依赖方式降低 CT26 细胞中的 Topo I 蛋白水平,在 1 μM 浓度下的抑制作用显著,且效果优于 SN-38、CH 及其物理混合物。
MN33-63 (1 μM; 72 h) 可下调 Bcl-2 表达并降低 CT26 细胞中总 caspase-3 蛋白水平,从而激活内源性凋亡通路。
MN33-63 (1 μM+ 2 μM MG132 (MS-L06849); 1 μM+ 50 μM chloroquine; 72 h) 可通过泛素-蛋白酶体和自噬-溶酶体两条通路促进 CT26 细胞中 Topo I 的降解;经 72 h 孵育后,MG132 和 chloroquine 可逆转 Topo I 的减少。

Cell Proliferation Assay

Cell Line: HCT-15, HeLa, HepG2, A549, HGC-27, CT26
Concentration: 0.038-100000 nM
Incubation Time: 72 h
Result: Exhibited broad-spectrum antiproliferative activity across all six cell lines, with IC50 values of 49.07 nM (HCT-15), 22.94 nM (HeLa), 9.47 nM (HepG2), 306.10 nM (A549), 0.05 nM (HGC-27), and 9.78 nM (CT26).
Showed superior potency to SN-38, CH, and their physical mixture in most cell lines, particularly exceptional activity against HGC-27 cells.

Western Blot Analysis

Cell Line: CT26
Concentration: 1-10000 nM, 1 μM
Incubation Time: 72 h
Result: Reduced Topo I protein levels in a dose-dependent manner, with significant inhibition observed at concentrations as low as 1 μM.
At 1 μM, inhibited Topo I expression more effectively than SN-38, CH, or their physical mixture.

Western Blot Analysis

Cell Line: CT26
Concentration: 1 μM
Incubation Time: 72 h
Result: Significantly downregulated Bcl-2 expression and reduced total caspase-3 protein levels (reflecting activation and cleavage of pro-caspase-3) compared to SN-38, CH, or their physical mixture.

Western Blot Analysis

Cell Line: CT26
Concentration: 1 μM MN33-63 + 2 μM MG132; 1 μM MN33-63 + 50 μM CQ
Incubation Time: 72 h
Result: The reduction in Topo I protein levels induced by MN33-63 was significantly reversed by both MG132 and CQ, indicating MN33-63 promotes Topo I degradation via the ubiquitin-proteasome and autophagy-lysosome pathways.
体内研究
(In Vivo)

MN33-63 (1.79-7.16 mg/kg;腹腔注射;每日一次;连续 10 天) 在荷 CT26 肿瘤的 BALB/c 小鼠中表现出剂量依赖性的强效抗肿瘤活性,高剂量组的肿瘤重量抑制率达 77.10%,且安全性良好,未观察到器官毒性或体重下降。

Animal Model: BALB/c mice with Colorectal cancer (female, 4-5 weeks old, 19-21 g, subcutaneous xenograft model)
Dosage: 1.79 mg/kg; 3.58 mg/kg; 7.16 mg/kg
Administration: i.p.; daily; 10 days
Result: Achieved a tumor weight inhibition rate of 77.10% at 7.16 mg/kg, significantly higher than CH monotherapy, SN-38 monotherapy, and CH + SN-38 physical mixture.
Drastically reduced tumor volume growth in all dose groups, with the 7.16 mg/kg group showing the smallest final tumor volumes.
Caused no body weight loss in any dose group.
Maintained serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CREA) levels within normal reference ranges in all dose groups.
Induced dose-dependent increases in tumor tissue necrotic areas, nuclear condensation, and cell apoptosis, with the 7.16 mg/kg group exhibiting the most extensive tumor cell damage.
Showed no abnormal pathological changes (inflammation, necrosis, degeneration) in heart, liver, spleen, lung, and kidney tissues in any dose group.

化学信息

分子量 684.37
分子式 C27H26Cl2N3Na2O9P

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础